Response to systemic therapies in patient-derived cell lines from primary and recurrent adult granulosa cell tumors

Abstract

In patients with the rare adult-type granulosa cell tumor tumor locations were cultured. On each cell line, 10 mono-(aGCT), surgery is the primary treatment for both primary and therapies and 17 combinations of drugs were tested. Carboplatin/ recurrent disease. In cases of inoperable disease, systematic gemcitabine showed efficacy and synergy in almost all patient-therapy is administered, but variable response rates and drug derived cell lines. Synergy could not be detected in the regular resistance complicate predicting the most effective therapy. Drug carboplatin/paclitaxel and carboplatin/etoposide combinations. screen testing on patient-derived cell lines may offer a solution. Experimental combinations alpelisib/fulvestrant and alpelisib/ In a national prospective study on aGCT, fresh tissue was cul- gemcitabine showed efficacy of more than 75%. Drug screens on tured into 2D cell lines, testing 27 clinical and experimental patient-derived tumor cell lines reflect the reality of the variable drugs. Dose–response curves and synergy were calculated using response of systemic therapy in patients with aGCT. In future GraphPad Prism and CompuSyn software. We established research, this technique may be used to personalize the systemic 34 patient-derived cell lines from tissue of 20 patients with aGCT. treatment of patients with aGCT in a clinical study. The good Of these, seven patients had a primary diagnosis of aGCT and response to carboplatin/gemcitabine in our patient-derived cell 13 patients had recurrent disease. In eight patients, multiple lines can then be confirmed in a clinical setting.